Table 4.
Laboratory findings and significant events during ICU stay
| Population of COVID-19 patients with extensive white matter microhemorrhages (n = 19) | Population of COVID-19 patients without extensive white matter microhemorrhages (n = 18) | p value | |
|---|---|---|---|
| Laboratory findings at the time of ICU admission | |||
| White blood cell count, × 109/L | 8.7 (4.9–12) | 6.9 (5.8–9.7) | 0.36 |
| Lymphocyte count, × 109/L | 0.71 (0.47–1.24) | 0.84 (0.68–1.12) | 0.6 |
| Haemoglobin, g/L | 119 (96–134) | 128 (118–137) | 0.18 |
| Platelet count, × 109/L | 200 (158–242) | 168 (160–272) | 0.68 |
| C-reactive protein, mg/L | 183 (112–281) | 119 (91–189) | 0.15 |
| Alanine aminotransferase U/L | 48 (30–63) | 43 (26–81) | 0.98 |
| Aspartate aminotransferase, U/L | 71 (59–91) | 64 (34–89) | 0.45 |
| Urea, mmol/L | 13 (8–17) | 7 (5–10) | 0.003 |
| Creatinine, µmol/L | 81 (69–248) | 79 (67–102) | 0.35 |
| Prothrombin time, s | 15.4 (14.3–16.1) | 14.8 (13.4–17.4) | 0.5 |
| Activated partial thromboplastin time, s | 39 (37–43) | 38 (36–40) | 0.43 |
| International normalized ratio (INR) | 1.17 (1.1–1.23) | 1.1 (1–1.35) | 0.35 |
| Antithrombin III (%) | 85 (72–96) | 94 (78–101) | 0.23 |
| Fibrinogen, g/L | 6.8 (6.3–7.8) | 6.2 (5.5–7.4) | 0.27 |
| d-dimers, mg/L | 3.1 (1.8–6.8) | 1.7 (1.1–2) | 0.01 |
| Laboratory findings during ICU stay and before brain MRI | |||
| Lower platelet count, × 109/L | 140 (108–204) | 163 (152–195) | 0.36 |
| Lower fibrinogen, g/L | 5.1 (4.5–5.8) | 5.8 (4.9–7.2) | 0.44 |
| Higher prothrombin time, s | 16.5 (15.9–17.5) | 17.4 (15.8–19) | 0.46 |
| Higher d-dimers, mg/L | 11.5 (7.5–20) | 4.6 (3–12) | 0.08 |
| Disseminated intravascular coagulation According to the criteria endorsed by the ISTH | 1 (5%) | 2 (11%) | 0.6 |
| Higher fibrinogen, g/L | 9 (7.6–10.4) | 8.8 (6.8–9.4) | 0.26 |
| Higher C-reactive protein, mg/L | 276 (185–382) | 196 (117–294) | 0.09 |
| Higher Creatinine, µmol/L | 293 (154–387) | 112 (91–220) | 0.04 |
| Lupus anticoagulant, data are n/N (%) | 15/19 (79%) | 10/12 (83%) | 1 |
| Thrombotic events during ICU stay | 7 (37%) | 2 (11%) | 0.12 |
| Treatment initiated during hospitalization before brain MRI | |||
| Dialysis | 12 (63%) | 5 (28%) | 0.04 |
| Anticoagulant therapy | 19 (100%) | 18 (100%) | 1 |
| Hydroxychloroquine | 7 (37%) | 8 (44%) | 0.74 |
| Lopinavir/ritonavir | 7 (37%) | 9 (50%) | 0.51 |
Data are number and percentage or median associated with first and third quartile
All statistical test results are in italics. Statistically significant results are in bold italics